Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Zachary Avigan

Assistant Professor

Icahn School of Medicine at Mount Sinai

United States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Articles (17)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (5)

Mary Linton Peters

Beth Israel Deaconess Medical Center

UNITED STATES

View details

Ioannis Vlachos

Broad Institute

UNITED STATES

View details

Christian Salib

Assistant Professor, Assistant Director of Hematopathology Services

Icahn School of Medicine at Mount Sinai

UNITED STATES

View details

Samir Parekh

Director, Center of Excellence for Multiple Myeloma

Icahn School of Medicine at Mount Sinai

UNITED STATES

View details

Suzanne Arinsburg

Mount Sinai Hospital

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Zachary Avigan

Research Interests

Make your next move.

Explore related searches

Articles (17)

Genomic features of clonal hematopoiesis–associated genes in primary and CAR T-cell–related secondary T-cell malignancies

Belantamab mafodotin, a BCMA-directed antibody-drug conjugate for multiple myeloma

Linvoseltamab, a BCMA-directed CD3 T-cell engager for multiple myeloma: a patient-centric option via a response-adapted dosing regimen

Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy

Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after BCMA-directed chimeric antigen receptor T cell therapy.

Author Correction: Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma (Bone Marrow Transplantation, (2024), 59, 10, (1440-1448), 10.1038/s41409-024-02385-1)

Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire

An evaluation of linvoseltamab for treatment of relapsed/refractory multiple myeloma

Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival

The role of 1q abnormalities in multiple myeloma: Genomic insights, clinical implications, and therapeutic challenges

Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma

Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials.

A novel application of XPO1 inhibition for the treatment of myelofibrosis

High CD34-positive cell dose in matched unrelated donor allogeneic hematopoietic stem cell transplant is not associated with graft-versus-host disease or mortality

Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia

Updated COVID‐19 clearance time among patients with cancer in the Delta and Omicron waves

Phase II clinical trial evaluating Abatacept in patients with steroid-refractory chronic graft versus host disease.

Collaborators (5)

Mary Linton Peters

Ioannis Vlachos

Christian Salib

Samir Parekh

Suzanne Arinsburg

Make your next move.